Acute Promyelocytic Leukemia: Two Ways to Injure a Heart, Choosing Between Them
Two induction regimens for high-risk APL, each of which will injure a 34-year-old's heart in a different decade. What nobody has yet established is whether her borderline QT is really hers or belongs to an uncorrected chemistry panel.
A.V., a 34-year-old graphic designer, arrived in the emergency department with gum bleeding and diffuse bruising she'd noticed over the preceding week, along with a headache severe enough that a CT was ordered before anyone suspected leukemia. Labs returned a white count of 46,000, a fibrinogen of 98 mg/dL and an INR of 1.6 — disseminated intravascular coagulation, which in this disease is not a complication of the leukemia so much as part of its presentation, and a fibrinogen that low in a patient who arrived with a headache is the finding that makes the next twenty-four hours dangerous whatever anyone decides about induction. Smear and marrow confirmed acute promyelocytic leukemia with the PML-RARA fusion. Her white count above 10,000 places her in the high-risk group, the one in which induction has historically leaned on chemotherapy rather than the arsenic-only approach validated in low-risk disease.
Both candidate regimens injure the heart. They differ in when the bill arrives. Idarubicin's anthracycline cardiotoxicity is cumulative and dose-dependent, which in a 34-year-old means a problem that surfaces in her fifties. Arsenic trioxide prolongs the QT interval, which means a problem that can surface this week — and her admission ECG already reads 468ms, with an unconfirmed long-QT diagnosis in a maternal cousin somewhere behind it. Two values a few lines below that ECG complicate the comparison before it properly begins: magnesium 1.5 and potassium 3.3, both low, both independently QT-prolonging, and both fixable in a matter of hours. Her echocardiogram is structurally normal with a preserved ejection fraction. So it is not yet established whether this is a genuine choice between two cardiac risks or an uncorrected chemistry panel making one of them look worse than it is — and that is a knowable thing, by repleting her and repeating the tracing, which nobody has done.
Hematology-oncology, induction planning
AIDA-based ATRA plus idarubicin is still the established approach for high-risk APL, and her QTc of 468 is close enough to danger that I'd rather not add an arsenic-trioxide-containing regimen on top of it for this induction course. One course of idarubicin is a known, manageable cardiac exposure; a prolonged QT in the setting of active leukemia and electrolyte derangement is a less predictable one.
I'd weigh the timeframes differently. Idarubicin's cardiotoxicity is cumulative and dose-dependent — it doesn't reveal itself in this induction course, it shows up as an ejection fraction problem a decade or two from now, in a 34-year-old who has that much time to lose. Her QT prolongation, by contrast, is borderline and has two correctable contributors sitting right in her chemistry panel.
'Known and manageable' undersells anthracycline cardiotoxicity — it's known specifically because it's been measured accumulating in survivors for decades, not because it's been shown to be safe at any dose in someone this young.
Before either of you finalizes which cardiac risk to accept, correct her magnesium and potassium and repeat the ECG. Hypomagnesemia and hypokalemia both prolong QT independently of any drug, and if her corrected QTc comes back meaningfully lower once her electrolytes are normal, this may not be the close call it looks like right now — it may just be an uncorrected chemistry panel making arsenic trioxide look riskier than it actually is for her.
Agreed: correct electrolytes first, reassess QTc, and proceed with ATRA-ATO-GO given the corrected interval came back well below the danger range — continuous telemetry maintained throughout induction regardless.
Not agreed: how much weight to give her family history of long QT syndrome in a maternal cousin, which no one could confirm genetically before treatment needed to start. The cardio-oncologist's plan — treat it as a soft signal lowering the threshold for telemetry-triggered dose interruption, not as grounds to avoid arsenic trioxide outright — was adopted without fully resolving how seriously an unconfirmed family history should be weighed in an urgent leukemia induction.